Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push the Chinese fusion protein company’s Covid-19 vaccine into Phase II/III testing and production planning.
Surface Oncology agreed to grant exclusive worldwide licensing rights to GlaxoSmithKline for the development and commercialization of the Cambridge, Mass.-based biotech company’s SRF813, a fully human IgG1 antibody and immunotherapy designed to treat cancer.
FDA Action Alert: Bristol Myers Squibb/Juno, Seattle Genetics, BioMarin and Tricida
Adeno-Associated Virus (AAV), B Cell Lymphomas, Biologics License Application (BLA), Brain Metastases, CAR-T Therapy, Chronic Kidney Disease, Diffuse large B-cell lymphoma (DLBCL), FDA, FDA/Regulatory, Hemophilia A, HER2-positive breast cancer, Immunotherapy, New Drug Applicationa, Project Orbis, Quarterly results, T-CellsThe U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma
FDA, FDA/Regulatory, Immunotherapy, New Drug Application Submission, Renal Cell Carcinoma (RCC), Tyrosine kinase inhibitors, Vascular Endothelial Growth Factor (VEGF) InhibitorsAVEO Oncology submitted a New Drug Application to the U.S. Food and Drug Administration for tivozanib, the company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, as a treatment for relapsed or refractory renal cell carcinoma (RCC).
More than 17.6 million American adults (about 7.5 percent) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as tree or grass pollen, and each person has their own set of problematic allergens.
The U.S. Food and Drug Administration approved Aimmune Therapeutics’ oral immunotherapy Palforzia as a first-of-its-kind treatment for the millions of people suffering from an allergy to peanuts.
Arcus Biosciences and Roche company Genentech are partnering on two clinical trials for colorectal and pancreatic cancer.
The U.S. Food and Drug Administration approved Astellas Pharma Inc. and Seattle Genetics Inc.’s experimental drug Padcev to treat advanced bladder cancer, about three months ahead of schedule.
Roche’s immunotherapy Tecentriq combined with the Swiss drugmaker’s Avastin medicine helped people with the most common form of liver cancer to live longer than with an older drug from Germany’s Bayer.
Merck Acquires Immune Design
Acquisitions, Business, Cancer, Cellular immunotherapy, Cellular immunotherapy, Chronic Diseases, Collaborations, Health Technology, Immune Cells, Immune System, Immunizations, Intratumoral TLR4 agonists, Investigational New Drug (INDs) submissions, Oncology, Sarcomas, Shares, Synovial sarcoma, T-CellsShares of Immune Design skyrocketed after Merck announced the acquisition of the Seattle-based oncology company for $300 million in cash.